Results 261 to 270 of about 19,354 (307)

Long-term outcomes of bioprosthetic tricuspid valves: a systematic review of studies published over the last 20 years. [PDF]

open access: yesEur Heart J Imaging Methods Pract
Zancanaro E   +10 more
europepmc   +1 more source

A Rare Case of Cardiac Prosthetic Mucormicosis: Things Are Not Always What They Seem.

open access: yesJ Cardiovasc Echogr
Rodríguez LG   +3 more
europepmc   +1 more source

Ten-year experience with sutureless Perceval bioprosthesis: single-centre analysis in 1157 implants

Journal of Cardiovascular Medicine, 2023
Aims We describe long-term clinical and echocardiographic outcomes in the largest single-centre cohort of patients who underwent aortic valve replacement (AVR) with sutureless Perceval (CorCym, Italy) bioprosthesis.
G. Concistré   +13 more
semanticscholar   +1 more source

Transcatheter valve‐in‐valve implantation versus surgical redo aortic root replacement in patients with degenerated freestyle aortic bioprosthesis

Catheterization and cardiovascular interventions, 2021
Transcatheter aortic valve‐in‐valve implantation (ViV TAVI) represents a new treatment option for patients with degenerated aortic bioprosthesis. Comparative data to redo surgical aortic valve replacement (redo SAVR) are limited.
Andrijana Vukadinovikj   +5 more
semanticscholar   +1 more source

Bioprosthesis in hand surgery

Journal of Surgical Research, 1986
In 1965, Carpentier coined the term bioprosthesis to distinguish the characteristics of glutaraldehyde-treated porcine heart valves from untreated or synthetic valves. Observation that the valves functioned normally but were not incorporated by the host has stimulated interest in similarly preserved materials for use in hand surgery.
D J, Smith   +4 more
openaire   +2 more sources

Surgical redo versus transseptal or transapical transcatheter mitral valve‐in‐valve implantation for failed mitral valve bioprosthesis

Catheterization and cardiovascular interventions, 2020
Redo surgical mitral valve replacement (SMVR) is the current standard of care for patients with failed bioprosthetic mitral valve (MV). Transcatheter mitral valve‐in‐valve replacement (TMViV) is arising as an alternative to SMVR in high risk patients. We
F. Simonetto   +18 more
semanticscholar   +1 more source

Hemodynamic features of the freestyle aortic bioprosthesis compared with stented bioprosthesis

The Annals of Thoracic Surgery, 1998
The Freestyle prosthesis is a new stentless aortic bioprosthesis. Anticipated benefits are improved hemodynamics and increased longevity.Doppler echocardiograms were performed early and at 3 to 6 months, 1 year, and 2 years after operation in 157 patients (69 men, 88 women, aged 48 to 85 years) with this prosthesis, and results were compared with ...
J G, Dumesnil   +7 more
openaire   +2 more sources

Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry.

EuroIntervention, 2019
AIMS The aim of this study was to compare the risk of prosthetic valve endocarditis (PVE) in patients with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR).
N. Moriyama   +22 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy